Abstract 4369686: Evaluating Lipid-Lowering Efficacy Of Obicetrapib: An Updated Meta-Analysis of Clinical Trials

Abstract

Introduction: Obicetrapib, a selective cholesteryl ester transfer protein (CETP) inhibitor, has demonstrated a reduction in low-density lipoprotein cholesterol (LDL-C) and apolipoprotein B (apoB) as a monotherapy or in combination with ezetimibe. This meta-analysis aimed to evaluate the lipid-lowering effect of a 10 mg dose of obicetrapib with placebo on a background of statins. Methods: A search was carried out in PubMed, Cochrane, and clinicaltrials.gov, where studies evaluating the efficacy of a 10 mg dose of obicetrapib with placebo on patients with a background of statins who had not achieved treatment goals. RevMan 5.4 version was used to evaluate the mean percentage difference in LDL, non-high-density lipoprotein cholesterol (non-HDL-C), high-density lipoprotein (HDL), apolipoprotein B (apoB), very-low-density lipoprotein (VLDL), and Triglyceride (TG) at 95% confidence interval (CI). P value <0.005 was considered significant. Results: We included a total of 6 studies comprising 3003 patients for analysis. Obicetrapib demostrated significantly greater reductions in LDL-C (mean difference [MD]: -37.36%; 95% CI: -41.44 to -33.28; p<0.00001); ApoB (MD: -24.35%; 95% CI: -28.35 to -20.35; p<0.00001) and non-HDL-C (MD: -32.37%; 95% CI: -34.27 to -30.47; p<0.00001) compared to those receiving a placebo. Furthermore, HDL-C levels in the obicetrapib group were significantly higher (MD: 156.21%; 95% CI: 146.40% to 166.02%; p<0.00001) compared with those receiving a placebo. VLDL-C levels were slightly higher in the obicetrapib group (MD: 4.59%; 95% CI: 1.24% to 7.93%; p=0.007) compared to placebo, while triglyceride levels did not differ significantly between the groups (MD: 3.17%; 95% CI: -4.42 to 10.75%; p=0.41). Conclusion: Obicetrapib demonstrated a significant reduction in atherogenic lipoproteins such as LDL-C, ApoB, and Non-HDL-C. Additionally, the HDL-C levels were significantly increased in the obicetrapib group. Further studies are needed to assess its impact on cardiovascular risk.